Sandoz Foresees Biosimilars Unlocking Innovation
Maximizing Access Allows Healthcare Systems To Invest Savings In New Treatments
Sandoz’ global head of biopharmaceuticals says that in the context of COVID-19, biosimilars can play a key role to increase access and unlock savings that can be invested in innovation to support “the long-term sustainability of healthcare systems.”
You may also be interested in...
Medicines for Europe and IQVIA have partnered to test biosimilar sustainability in 12 European countries by issuing scorecards that measure the contribution of a country’s biosimilar policies to health systems.
Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.
Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast.